Audit in process? Call the number on your audit letter to get options.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
August 28, 2018 - The FDA announced the permanent discontinuation of AstraZeneca’s Lynparza (olaparib) 50 mg capsules.
Download PDF
Return to publications